Identification of biomarkers for overall survival of patients with metastatic renal cell carcinoma treated with MGN1601.
Viktor Grünwald(Deutsche Schmerzgesellschaft), Burghardt Wittig, Stefan Hauser(German Center for Neurodegenerative Diseases), Marina Tschaika(Bristol-Myers Squibb (United States)), Ekaterina Weith(Mologen (Germany)), Manuel Schmidt(Mologen (Germany)), Ingo G.H. Schmidt‐Wolf(University Hospital Bonn), Steffen Weikert(St. Hedwig-Krankenhaus), Matthias Schroff(Mologen (Germany))
Cited by 1
Related Papers
The Epidemiology of Renal Cell Carcinoma
|European Urology|2011|1k
<i>RUNX1</i>Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
|Journal of Clinical Oncology|2011|450
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
|The Lancet Oncology|2017|431
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2020|421
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380